Druker, Brian J.

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine

Gastrointestinal Tumor Research and TreatmentMast cells and histamine

Cited by 4,389

Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 2,713

In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 1,036

Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma

Gillette, M. A., Satpathy, S., Cao, S., Dhanasekaran, S. M., Vasaikar, S. V., Krug, K., Petralia, F., Li, Y., Liang, W.-W., Reva, B., et al. (2020) · Cell

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 820

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

Cortes, J. E., Kantarjian, H., Shah, N. P., Bixby, D., Mauro, M. J., Flinn, I., O'Hare, T., Hu, S., Narasimhan, N. I., Rivera, V. M., et al. (2012) · New England Journal of Medicine

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 769

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 765

Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma

Clark, D. J., Dhanasekaran, S. M., Petralia, F., Pan, J., Song, X., Hu, Y., da Veiga Leprevost, F., Reva, B., Lih, T.-S. M., Chang, H.-Y., et al. (2019) · Cell

Renal cell carcinoma treatmentCancer Genomics and Diagnostics

Cited by 730

Proteogenomic and metabolomic characterization of human glioblastoma

Wang, L.-B., Karpova, A., Gritsenko, M. A., Kyle, J. E., Cao, S., Li, Y., Rykunov, D., Colaprico, A., Rothstein, J. H., Hong, R., et al. (2021) · Cancer Cell

Glioma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 661

Gene expression changes associated with progression and response in chronic myeloid leukemia

Radich, J. P., Dai, H., Mao, M., Oehler, V., Schelter, J., Druker, B., Sawyers, C., Shah, N., Stock, W., Willman, C. L., et al. (2006) · Proceedings of the National Academy of Sciences

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 583

Proteogenomic characterization of pancreatic ductal adenocarcinoma

Cao, L., Huang, C., Cui Zhou, D., Hu, Y., Lih, T. M., Savage, S. R., Krug, K., Clark, D. J., Schnaubelt, M., Chen, L., et al. (2021) · Cell

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 578

Proteogenomic Characterization of Endometrial Carcinoma

Dou, Y., Kawaler, E. A., Cui Zhou, D., Gritsenko, M. A., Huang, C., Blumenberg, L., Karpova, A., Petyuk, V. A., Savage, S. R., Satpathy, S., et al. (2020) · Cell

Endometrial and Cervical Cancer TreatmentsAdvanced Proteomics Techniques and Applications

Cited by 485

Integrative Analysis of Drug Response and Clinical Outcome in Acute Myeloid Leukemia

Bottomly, D., Long, N., Schultz, A. R., Kurtz, S. E., Tognon, C. E., Johnson, K., Abel, M., Agarwal, A., Avaylon, S., Benton, E., et al. (2022) · Cancer Cell

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 403

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

Bradeen, H. A., Eide, C. A., O'Hare, T., Johnson, K. J., Willis, S. G., Lee, F. Y., Druker, B. J., & Deininger, M. W. (2006) · Blood

Chronic Myeloid Leukemia TreatmentsLung Cancer Treatments and Mutations

Cited by 393

Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia

Carey, A., Edwards, D. K., Eide, C. A., Newell, L., Traer, E., Medeiros, B. C., Pollyea, D. A., Deininger, M. W., Collins, R. H., Tyner, J. W., et al. (2017) · Cell Reports

Acute Myeloid Leukemia ResearchCytokine Signaling Pathways and Interactions

Cited by 270

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants

Eide, C. A., Zabriskie, M. S., Savage Stevens, S. L., Antelope, O., Vellore, N. A., Than, H., Schultz, A. R., Clair, P., Bowler, A. D., Pomicter, A. D., et al. (2019) · Cancer Cell

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 247

An expanded universe of cancer targets

Hahn, W. C., Bader, J. S., Braun, T. P., Califano, A., Clemons, P. A., Druker, B. J., Ewald, A. J., Fu, H., Jagu, S., Kemp, C. J., et al. (2021) · Cell

Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer

Cited by 213

Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation

Burslem, G. M., Schultz, A. R., Bondeson, D. P., Eide, C. A., Savage Stevens, S. L., Druker, B. J., & Crews, C. M. (2019) · Cancer Research

Protein Degradation and InhibitorsChronic Myeloid Leukemia Treatments

Cited by 212

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

on behalf of the International CML Foundation Genomics Alliance, Branford, S., Kim, D. D. H., Apperley, J. F., Eide, C. A., Mustjoki, S., Ong, S. T., Nteliopoulos, G., Ernst, T., Chuah, C., et al. (2019) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 149

Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin

Liang, W.-W., Lu, R. J.-H., Jayasinghe, R. G., Foltz, S. M., Porta-Pardo, E., Geffen, Y., Wendl, M. C., Lazcano, R., Kolodziejczak, I., Song, Y., et al. (2023) · Cancer Cell

Epigenetics and DNA MethylationCancer Genomics and Diagnostics

Cited by 105

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors

Pietarinen, P. O., Eide, C. A., Ayuda-Durán, P., Potdar, S., Kuusanmäki, H., Andersson, E. I., Mpindi, J. P., Pemovska, T., Kontro, M., Heckman, C. A., et al. (2017) · Oncotarget

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 16